All In Biotech

Drug Trial Radar · NCT05286931

SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

Evaluation of SpeeDx's Ciprofloxacin gyrA Assay for Clinical Care of STD Clinic Patients With Neisseria Gonorrhea

Last checked: Nov 20, 2026Latest source record: Mar 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Mar 3, 2022

Primary completion

Dec 31, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.

Conditions

  • Neisseria Gonorrhoeae Infection

Interventions

  • Ciprofloxacin 500 mgDrug

    Ciprofloxacin 500 MG, taken once orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the number and proportion of Neisseria Gonorrhea (NG) cases that can be cured with ciprofloxacinTime frame: 2 years
  2. To determine the effectiveness of treating patients with Neisseria Gonorrhea gyrA wildtype with Ciprofloxacin 500 mg orally onceTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Public Health -- Seattle & King County Sexual Health Clinic

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.